NEULANDLAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.2
| Stock Code | NEULANDLAB | Market Cap | 17,167 Cr. | Current Price | 13,392 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 88.0 | Book Value | 1,257 ₹ | Dividend Yield | 0.09 % | ROCE | 18.7 % |
| ROE | 14.8 % | Face Value | 10.0 ₹ | DMA 50 | 14,649 ₹ | DMA 200 | 14,364 ₹ |
| Chg in FII Hold | 0.30 % | Chg in DII Hold | 1.17 % | PAT Qtr | 96.5 Cr. | PAT Prev Qtr | 13.7 Cr. |
| RSI | 41.7 | MACD | -589 | Volume | 36,152 | Avg Vol 1Wk | 44,194 |
| Low price | 10,060 ₹ | High price | 19,748 ₹ | PEG Ratio | 1.86 | Debt to equity | 0.16 |
| 52w Index | 34.4 % | Qtr Profit Var | 202 % | EPS | 187 ₹ | Industry PE | 29.2 |
📊 Analysis: NEULANDLAB shows weak-to-moderate intraday potential. Current price (13,392 ₹) is below both 50 DMA (14,649 ₹) and 200 DMA (14,364 ₹), indicating short-term weakness. RSI at 41.7 suggests oversold territory, while MACD (-589) confirms strong bearish momentum. Volume (36K) is below average (44K), reducing conviction for intraday moves. Price action favors cautious scalps near support with strict stop-loss discipline.
💰 Optimal Buy Price: 13,300 ₹ – 13,400 ₹ (near support zone)
📈 Profit-Taking Levels: 13,550 ₹ – 13,700 ₹
📉 Stop-Loss / Loss Protection: 13,150 ₹
⏱️ If Already Holding: Exit intraday if price fails to hold above 13,300 ₹ or if RSI dips below 40. Book profits if price approaches 13,550–13,700 ₹ with weakening momentum or volume divergence.
Positive
- EPS of 187 ₹ reflects strong earnings base.
- Quarterly PAT improved significantly (96.5 Cr. vs 13.7 Cr.), showing sharp growth.
- ROCE (18.7%) and ROE (14.8%) indicate decent efficiency.
- FII holdings increased (+0.30%) and DII holdings increased (+1.17%), showing institutional support.
- Debt-to-equity ratio of 0.16 indicates manageable leverage.
Limitation
- High P/E (88.0) compared to industry average (29.2) signals overvaluation.
- Dividend yield of 0.09% is negligible.
- Stock trading below both DMA 50 and DMA 200 confirms short-term weakness.
- Volume below average weakens intraday conviction.
Company Negative News
- MACD strongly negative (-589), confirming bearish momentum.
- 52-week index at 34.4% shows weak recovery from highs.
Company Positive News
- Quarterly profit variation (+202%) highlights strong earnings momentum.
- Institutional inflows (FII and DII increases) support fundamentals.
Industry
- Industry P/E at 29.2 is much lower than NEULANDLAB’s (88.0), suggesting sector is cheaper.
- Pharmaceutical sector remains resilient with global demand, though valuations are stretched.
Conclusion
⚖️ NEULANDLAB is a weak-to-moderate candidate for intraday trading today. Fundamentals show strong earnings growth and institutional support, but technical indicators highlight short-term weakness and stretched valuations. Best suited for cautious scalps near support with tight stop-loss discipline and profit booking around 13,550–13,700 ₹.
Would you like me to also prepare a workflow-ready HTML template with peer benchmarking overlays (e.g., comparing NEULANDLAB with Divi’s Labs, Laurus Labs, and Aurobindo Pharma) so you can integrate sector-relative strength into your intraday reports?